Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 1
2017 1
2018 1
2019 2
2020 1
2021 5
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Targeting two radiation-induced immunosuppressive pathways to improve the efficacy of normofractionated radiation therapy in a preclinical colorectal cancer model.
Boustani J, Lecoester B, Baude J, Latour C, Limagne E, Ladjohoulou R, Morgand V, Froidurot L, Ghiringhelli F, Truc G, Adotévi O, Mirjolet C. Boustani J, et al. Int J Radiat Biol. 2024 Mar 20:1-10. doi: 10.1080/09553002.2024.2331115. Online ahead of print. Int J Radiat Biol. 2024. PMID: 38506658
Managing postoperative biochemical relapse in prostate cancer, from the perspective of the Francophone group of Urological radiotherapy (GFRU).
Ah-Thiane L, Sargos P, Chapet O, Jolicoeur M, Terlizzi M, Salembier C, Boustani J, Prevost C, Gaudioz S, Derashodian T, Palumbo S, De Hertogh O, Créhange G, Zilli T, Supiot S. Ah-Thiane L, et al. Among authors: boustani j. Cancer Treat Rev. 2023 Nov;120:102626. doi: 10.1016/j.ctrv.2023.102626. Epub 2023 Sep 16. Cancer Treat Rev. 2023. PMID: 37734178 Review.
Chemotherapy to potentiate the radiation-induced immune response.
Lecoester B, Wespiser M, Marguier A, Mirjolet C, Boustani J, Adotévi O. Lecoester B, et al. Among authors: boustani j. Int Rev Cell Mol Biol. 2023;376:143-173. doi: 10.1016/bs.ircmb.2023.01.004. Epub 2023 Feb 11. Int Rev Cell Mol Biol. 2023. PMID: 36997268 Review.
Salvage Involved-Field and Extended-Field Radiation Therapy in Positron Emission Tomography-Positive Nodal Recurrent Prostate Cancer: Outcomes and Patterns of Failure.
Pêtre A, Quivrin M, Briot N, Boustani J, Martin E, Bessieres I, Cochet A, Créhange G. Pêtre A, et al. Among authors: boustani j. Adv Radiat Oncol. 2022 Jul 28;8(1):101040. doi: 10.1016/j.adro.2022.101040. eCollection 2023 Jan-Feb. Adv Radiat Oncol. 2022. PMID: 36483057 Free PMC article.
Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.
Kim S, Boustani J, Vernerey D, Vendrely V, Evesque L, Francois E, Quero L, Ghiringhelli F, de la Fouchardière C, Dahan L, Bouché O, Chibaudel B, Hajbi FE, Vernet C, Rebucci-Peixoto M, Feuersinger A, Maritaz C, Borg C. Kim S, et al. Among authors: boustani j. Front Oncol. 2022 Aug 24;12:918499. doi: 10.3389/fonc.2022.918499. eCollection 2022. Front Oncol. 2022. PMID: 36119522 Free PMC article.
Present and Future Research on Anal Squamous Cell Carcinoma.
Spehner L, Boustani J, Cabel L, Doyen J, Vienot A, Borg C, Kim S. Spehner L, et al. Among authors: boustani j. Cancers (Basel). 2021 Aug 2;13(15):3895. doi: 10.3390/cancers13153895. Cancers (Basel). 2021. PMID: 34359795 Free PMC article. Review.
20 results